12:00 AM
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

C225: Began Phase III trial

ImClone Systems Inc. (IMCL), New York, N.Y.
Product: C225
Business: Cancer
Therapeutic category: Antibody
Target: Epidermal growth factor (EGF) receptor

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >